Inactivating

Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential to acquire mutations with resistance to treatment and disease progression. To identify potentially targetable mutations in advanced breast cancer, we performed prospective molecular characterization of a cohort of patients with ABC. Biopsies from patients with advanced breast cancer were sequenced with a 41 genes targeted panel in the ABC Biopsy (ABC-Bio) study. Blood samples were collected at disease progression for circulating tumor DNA (ctDNA) analysis, along with matched primary tumor to assess for acquisition in ABC in a subset of patients. We sequenced 210 ABC samples, demonstrating enrichment compared with primary disease for potentially targetable mutations in Our research identifies multiple therapeutic opportunities for advanced breast cancer and identifies the previously underappreciated acquisition of

Informations de copyright

©2019 American Association for Cancer Research.